Comparison of Genomic Profiling Data with Clinical Parameters: Implications for Breast Cancer Prognosis.

ABSTRACT: Precise prognosis is crucial for selection of adjuvant therapy in breast cancer. Molecular subtyping is increasingly used to complement immunohistochemical and pathological classification and to predict recurrence. This study compares both outcomes in a clinical setting. Molecular subtyping (MammaPrint^®, TargetPrint^®, and BluePrint^®) and pathological classification data were compared in a cohort of 143 breast cancer patients. High risk clinical factors were defined by a value of the proliferation factor Ki67 equal or higher than 14% and/or high histological grade. The results from molecular classification were considered as reference. Core needle biopsies were found to be comparable to surgery samples for molecular classification. Discrepancies were found b

SUBMITTER: Lopez-Ruiz JA 

PROVIDER: S-EPMC9454811 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature